Gut bacterial type III secretion systems aggravate colitis in mice and serve as biomarkers of Crohn's disease.

Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE

Original Publication: [Amsterdam] : Elsevier B.V., [2014]-

Crohn Disease*/microbiology ; Crohn Disease*/metabolism ; Crohn Disease*/pathology ; Biomarkers* ; Disease Models, Animal* ; Gastrointestinal Microbiome* ; Type III Secretion Systems*/metabolism ; Type III Secretion Systems*/genetics; Animals ; Mice ; Humans ; Colitis/microbiology ; Colitis/metabolism ; Metagenomics/methods ; Feces/microbiology ; Female ; Male

Background: Mesenteric adipose tissue (mAT) hyperplasia, known as creeping fat, is a pathologic characteristic of Crohn's disease (CD). In our previously reported cohort, we observed that Achromobacter pulmonis was the most abundant and prevalent bacteria cultivated from creeping fat.
Methods: A whole genomic sequencing and identification of T3SS orthologs of mAT-derived A. pulmonis were used. A functional type III secretion system (T3SS) mediated the pathogenic potential of A. pulmonis in vitro and in mouse colitis model. Furthermore, a T3SS Finder pipeline was introduced to evaluate gut bacterial T3SS orthologs in the feces of CD patients, ulcerative colitis and colorectal cancer patients.
Findings: Here, we reveal that mAT-derived A. pulmonis possesses a functional T3SS, aggravates colitis in mice via T3SS, and exhibits T3SS-dependent cytotoxicity via a caspase-independent mechanism in macrophages and epithelial cells, which demonstrated the pathogenic potential of the T3SS-harboring A. pulmonis. Metagenomic analyses demonstrate an increased abundance of Achromobacter in the fecal of Crohn's disease patients compared to healthy controls. A comprehensive comparison of total microbial vT3SS abundance in various intestine diseases demonstrated that the specific enrichment of vT3SS genes was shown in fecal samples of CD, neither ulcerative colitis nor colorectal cancer patients, and ten T3SS gene-based biomarkers for CD were discovered and validated in a newly recruited CD cohort. Furthermore, treatment with exclusive enteral nutrition (EEN), an intervention that improves CD patient symptomatology, was found associated with a significant reduction in the prevalence of T3SS genes in fecal samples.
Interpretation: These findings highlight the pathogenic significance of T3SSs in the context of CD and identify specific T3SS genes that could potentially function as biomarkers for diagnosing and monitoring the clinical status of CD patients.
Funding: This work is supported by the National Key Research and Development Program of China (2020YFA0907800), the China Postdoctoral Science Foundation (2023M744089), the National Natural Science Foundation of China (32000096), the Shenzhen Science and Technology Programs (KQTD20200820145822023, RCIC20231211085944057, and ZDSYS20220606100803007), National Key Clinical Discipline, Guangdong Provincial Clinical Research Center for Digestive Diseases (2020B1111170004), Qingfeng Scientific Research Fund of the China Crohn's & Colitis Foundation (CCCF) (CCCF-QF-2022B71-1), and the Sixth Affiliated Hospital, Sun Yat-sen University Clinical Research 1010 Program 1010CG(2023)-08. These funding provided well support for this research work, which involved data collection, analysis, interpretation, patient recruitment and so on.
Competing Interests: Declaration of interests The authors declare no competing interests.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

Methods Mol Biol. 2018;1784:29-33. (PMID: 29761385)
Infect Immun. 2010 Dec;78(12):5086-98. (PMID: 20876291)
BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040)
Bioinformatics. 2012 Dec 1;28(23):3150-2. (PMID: 23060610)
Cell Microbiol. 2009 Dec;11(12):1735-49. (PMID: 19650828)
Nat Protoc. 2016 Sep;11(9):1650-67. (PMID: 27560171)
Microb Genom. 2021 Jul;7(7):. (PMID: 34292148)
Nat Commun. 2019 May 16;10(1):2182. (PMID: 31097708)
Nat Biotechnol. 2020 Sep;38(9):1098. (PMID: 32887961)
Bioinformatics. 2015 May 15;31(10):1674-6. (PMID: 25609793)
Comput Struct Biotechnol J. 2021 Aug 03;19:4641-4657. (PMID: 34504660)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
J Biol Stand. 1985 Apr;13(2):129-34. (PMID: 2860114)
Nat Rev Immunol. 2011 Oct 25;11(11):750-61. (PMID: 22025054)
Nucleic Acids Res. 2010 May;38(8):2624-36. (PMID: 20385581)
Microbiome. 2022 Sep 16;10(1):149. (PMID: 36114582)
Curr Microbiol. 2012 Dec;65(6):673-8. (PMID: 22926720)
Nature. 2006 Mar 9;440(7081):228-32. (PMID: 16407890)
Bioinformatics. 2018 Sep 1;34(17):i884-i890. (PMID: 30423086)
Nature. 2019 May;569(7758):655-662. (PMID: 31142855)
Nat Rev Microbiol. 2015 Apr;13(4):206-16. (PMID: 25749454)
Microbiome. 2021 Nov 23;9(1):228. (PMID: 34814945)
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595. (PMID: 28594827)
Nat Rev Microbiol. 2019 Aug;17(8):497-511. (PMID: 31249397)
Cell Microbiol. 2003 Feb;5(2):123-32. (PMID: 12580948)
PLoS Biol. 2018 Jul 3;16(7):e2005970. (PMID: 29969450)
Sci Rep. 2020 Apr 7;10(1):5997. (PMID: 32265475)
Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308)
Mol Microbiol. 2005 Oct;58(1):267-79. (PMID: 16164564)
Ann Am Thorac Soc. 2015 Feb;12(2):252-8. (PMID: 25706494)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Eur J Cell Biol. 2023 Dec;102(4):151358. (PMID: 37703749)
Chem Sci. 2022 Oct 11;13(42):12445-12460. (PMID: 36382278)
Nature. 2023 Mar;615(7950):168-174. (PMID: 36813961)
Mol Cell. 2022 Aug 4;82(15):2844-2857.e10. (PMID: 35662396)
Mol Cell Biochem. 2013 Aug;380(1-2):97-106. (PMID: 23615711)
ILAR J. 2005;46(3):269-79. (PMID: 15953834)
Infect Immun. 2008 Mar;76(3):1257-66. (PMID: 18195025)
Gut Microbes. 2020 Jul 3;11(4):918-929. (PMID: 31971861)
Microbiol Spectr. 2024 Mar 5;12(3):e0295323. (PMID: 38315029)
World J Gastroenterol. 2013 Nov 21;19(43):7652-60. (PMID: 24282355)
Mol Biol Evol. 2015 Jan;32(1):268-74. (PMID: 25371430)
Nat Rev Microbiol. 2017 Jun;15(6):323-337. (PMID: 28392566)
Nat Rev Dis Primers. 2020 Apr 2;6(1):22. (PMID: 32242028)
Clin Microbiol Rev. 2023 Sep 21;36(3):e0016422. (PMID: 37306571)
Stem Cells Transl Med. 2018 Jun;7(6):456-467. (PMID: 29635868)
Nat Microbiol. 2022 Apr;7(4):497-507. (PMID: 35365784)
Nat Methods. 2015 Jan;12(1):59-60. (PMID: 25402007)
Front Biosci (Landmark Ed). 2021 Dec 30;26(12):1613-1620. (PMID: 34994175)
Nucleic Acids Res. 2023 Jul 5;51(W1):W587-W592. (PMID: 37144476)
Trends Biochem Sci. 2016 Feb;41(2):175-189. (PMID: 26520801)
J Crohns Colitis. 2018 Nov 09;12(10):1139-1150. (PMID: 29309546)
Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):6452-6457. (PMID: 29866849)
Nat Methods. 2015 Apr;12(4):357-60. (PMID: 25751142)
Evolution. 1985 Jul;39(4):783-791. (PMID: 28561359)
J Dig Dis. 2019 Sep;20(9):447-459. (PMID: 31240835)
Cell. 2020 Oct 29;183(3):666-683.e17. (PMID: 32991841)
Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):2341-8. (PMID: 26884180)
Antimicrob Agents Chemother. 2020 Oct 20;64(11):. (PMID: 32816734)
Nat Methods. 2017 Apr;14(4):417-419. (PMID: 28263959)
Cell. 2020 Mar 5;180(5):941-955.e20. (PMID: 32109412)
Gigascience. 2017 Jul 1;6(7):1-11. (PMID: 28655159)
Bioinformatics. 2019 Nov 15;:. (PMID: 31730192)
Nature. 2021 Jul;595(7865):91-95. (PMID: 34163075)
Cell Host Microbe. 2014 Mar 12;15(3):382-392. (PMID: 24629344)
J Clin Immunol. 2021 Oct;41(7):1686-1692. (PMID: 34263392)
Cold Spring Harb Protoc. 2011 Aug 01;2011(8):993-4. (PMID: 21807853)
Cell Death Differ. 2021 Aug;28(8):2305-2314. (PMID: 34290396)
Nat Commun. 2021 Nov 19;12(1):6757. (PMID: 34799562)
Cell. 2022 Jul 7;185(14):2495-2509.e11. (PMID: 35764090)
Cell Host Microbe. 2009 Jun 18;5(6):571-9. (PMID: 19527884)

Keywords: Achromobacter pulmonis; Crohn’s disease; Cytotoxicity; Exclusive enteral nutrition; Type III secretion system

0 (Biomarkers)
0 (Type III Secretion Systems)

Date Created: 20240831 Date Completed: 20240913 Latest Revision: 20240917

20240917

PMC11402190

10.1016/j.ebiom.2024.105296

39216231